TheraKey:
Digital therapy assistance with gen AI

The best thing about gen AI? When it serves a truly good purpose. TheraKey was launched in 2012 as an information portal and has since evolved, in collaboration with IBM iX, into a personalized therapy support program for chronic diseases

How can we make things easier for patients?

 

For patients living with chronic diseases, managing their condition can be overwhelming. The internet provides an abundance of information, but it’s difficult to assess the credibility of sources, and the sheer volume of information can be staggering.

Moreover, therapy adherence is a significant challenge, and many patients struggle to stick to their treatment plans. Healthcare professionals also face the daunting task of providing personalized support to their patients while having to keep up with the latest research and guidelines.

 

A digital therapy support program

Berlin-Chemie, in collaboration with IBM iX, has set out to revolutionize the management of chronic diseases by harnessing the power of digital tools and gen AI. They developed TheraKey, a personalized therapy support program that provides patients, healthcare professionals and relatives with scientifically validated information and individual resources to support therapy management. Users simply enter a personal code and configure a profile to receive relevant information about their illness. TheraKey supports eight indicators, including type 1 and type 2 diabetes, asthma and COPD (chronic obstructive pulmonary disease).

By integrating the gen AI chatbot ISA, which combines artificial intelligence and scientifically verified data, into the platform, TheraKey was able to provide quick and direct answers to patients’ questions about COPD. This helped to further enhance the user experience and improve therapy outcomes.

Together for better health

Patients are more likely to adhere to their treatment plans when they have access to reliable, personalized information and support.

By providing them with targeted resources, protocol features, assignments and quizzes, among other things, TheraKey helped empower users and professionals. These measures allow more effective therapy support and can help improve the quality of life of those affected and their relatives. As research is constantly progressing, of course also TheraKey is continuously being developed further.

 

More Cases

Let’s get started!

Work with our experts to stay in pole position for the generative AI race!

Tanja Waldeck
IBM iX Leader DACH
Jean-Henrik Zitterbart
Industry Leader Banking & Financial Markets DACH, IBM Consulting